Xiaqing Xu

558 total citations
14 papers, 358 citations indexed

About

Xiaqing Xu is a scholar working on Molecular Biology, Oncology and Immunology. According to data from OpenAlex, Xiaqing Xu has authored 14 papers receiving a total of 358 indexed citations (citations by other indexed papers that have themselves been cited), including 6 papers in Molecular Biology, 5 papers in Oncology and 3 papers in Immunology. Recurrent topics in Xiaqing Xu's work include Cancer Immunotherapy and Biomarkers (3 papers), Infant Development and Preterm Care (2 papers) and Epigenetics and DNA Methylation (2 papers). Xiaqing Xu is often cited by papers focused on Cancer Immunotherapy and Biomarkers (3 papers), Infant Development and Preterm Care (2 papers) and Epigenetics and DNA Methylation (2 papers). Xiaqing Xu collaborates with scholars based in China, Canada and New Zealand. Xiaqing Xu's co-authors include Ling Ding, Qiaojun He, Xi Chen, Bo Yang, Honghai Wu, Zhangting Yao, Guikai Liang, Xiaohui Pan, Yuli Qian and Jieqiong Zhang and has published in prestigious journals such as Journal of Clinical Investigation, European Journal of Pharmacology and Frontiers in Pharmacology.

In The Last Decade

Xiaqing Xu

12 papers receiving 356 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Xiaqing Xu China	7	184	173	119	70	58	14	358
Wentao Tian China	7	226 1.2×	155 0.9×	98 0.8×	95 1.4×	78 1.3×	15	454
Diane Costanzo-Garvey United States	9	122 0.7×	118 0.7×	80 0.7×	42 0.6×	53 0.9×	12	283
Elena Tutunea-Fatan Canada	9	176 1.0×	185 1.1×	83 0.7×	30 0.4×	73 1.3×	15	387
Jinfeng Gan China	10	98 0.5×	203 1.2×	51 0.4×	47 0.7×	91 1.6×	21	324
Handan Xiang United States	8	146 0.8×	236 1.4×	149 1.3×	29 0.4×	105 1.8×	10	424
Yongkang Zou China	8	110 0.6×	203 1.2×	59 0.5×	63 0.9×	86 1.5×	14	340
Tongguan Tian China	7	80 0.4×	154 0.9×	80 0.7×	44 0.6×	58 1.0×	13	284
Yubin Lei China	10	108 0.6×	250 1.4×	57 0.5×	38 0.5×	129 2.2×	22	386
Rujun Mo China	13	115 0.6×	282 1.6×	67 0.6×	120 1.7×	147 2.5×	21	454
Yongsheng Li China	8	84 0.5×	238 1.4×	85 0.7×	56 0.8×	151 2.6×	14	385

Countries citing papers authored by Xiaqing Xu

Since Specialization

Citations

This map shows the geographic impact of Xiaqing Xu's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Xiaqing Xu with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Xiaqing Xu more than expected).

Fields of papers citing papers by Xiaqing Xu

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Xiaqing Xu. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Xiaqing Xu. The network helps show where Xiaqing Xu may publish in the future.

Co-authorship network of co-authors of Xiaqing Xu

This figure shows the co-authorship network connecting the top 25 collaborators of Xiaqing Xu. A scholar is included among the top collaborators of Xiaqing Xu based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Xiaqing Xu. Xiaqing Xu is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

14 of 14 papers shown

Zhang, Wei, Yimin Ge, & Xiaqing Xu. (2025). BMP-9 promotes the expression of PD-L1 in osteosarcoma cells through FOXO1. Medical Oncology. 42(12). 535–535.

Xu, Xiaqing, Qian Liu, Yiqing Zhang, et al.. (2025). Pharmacological targeting of HDAC/BET pathway enhances 5-FU efficacy in esophageal squamous cancer cells. Archives of Pharmacal Research. 48(11-12). 1362–1381.

Xu, Xiaqing, et al.. (2025). Motor-Based Interventions in Children with Developmental Coordination Disorder: A Systematic Review and Meta-analysis of Randomised Controlled Trials. Sports Medicine - Open. 11(1). 59–59. 1 indexed citations

Li, Huaqiang, et al.. (2024). The prevalence of developmental coordination disorder in children: a systematic review and meta-analysis. Frontiers in Pediatrics. 12. 1387406–1387406. 4 indexed citations

Liu, Zicai, Hao Hu, Xuejin Liu, et al.. (2023). Baduanjin improves neck pain and functional movement in middle-aged and elderly people: A systematic review and meta-analysis of randomized controlled trials. Frontiers in Medicine. 9. 920102–920102. 6 indexed citations

Ding, Ling, Xi Chen, Wenxin Zhang, et al.. (2023). Canagliflozin primes antitumor immunity by triggering PD-L1 degradation in endocytic recycling. Journal of Clinical Investigation. 133(1). 48 indexed citations

Xu, Xiaqing, Jiaxing Chen, Wenxing Li, et al.. (2023). Immunology and immunotherapy in gastric cancer. Clinical and Experimental Medicine. 23(7). 3189–3204. 19 indexed citations

Wang, Jian, Xiaqing Xu, Tingting Wang, et al.. (2021). Ceritinib increases sensitivity of AKT inhibitors to gastric cancer. European Journal of Pharmacology. 896. 173879–173879. 4 indexed citations

Pan, Xiaohui, Hongjie Guo, Wenxin Zhang, et al.. (2021). Dihydropyridine Calcium Channel Blockers Suppress the Transcription of PD-L1 by Inhibiting the Activation of STAT1. Frontiers in Pharmacology. 11. 539261–539261. 27 indexed citations

10.

Chang, Linlin, Xiaqing Xu, Xueling Liu, et al.. (2021). Emerging role of m6A methylation modification in ovarian cancer. Cancer Cell International. 21(1). 663–663. 16 indexed citations

11.

Xu, Xiaqing, Xiaohui Pan, Tingting Wang, et al.. (2020). Intrinsic and acquired resistance to CDK4/6 inhibitors and potential overcoming strategies. Acta Pharmacologica Sinica. 42(2). 171–178. 45 indexed citations

12.

Xu, Xiaqing, Honggang Lou, Youyou Yan, et al.. (2020). Hyperglycemia decreases anti-cancer efficiency of adriamycin via AMPK pathway. Endocrine Related Cancer. 27(2). X3–X4. 2 indexed citations

13.

Ding, Ling, Xi Chen, Xiaqing Xu, et al.. (2018). PARP1 Suppresses the Transcription of PD-L1 by Poly(ADP-Ribosyl)ating STAT3. Cancer Immunology Research. 7(1). 136–149. 98 indexed citations

14.

Yao, Zhangting, Jieqiong Zhang, Bo Zhang, et al.. (2018). Imatinib prevents lung cancer metastasis by inhibiting M2-like polarization of macrophages. Pharmacological Research. 133. 121–131. 88 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact